TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06801509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose
Description: Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose
Description: Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control: Saline
Description: The placebo in this study is 0.9% sodium chloride (normal saline) injection; Immunization procedure: 2 doses, 60 days apart;

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix®
Description: Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Dosage of vaccination: 50 μg; Immunization procedure: 2 doses, 60 days apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ganwei®
Description: Route of vaccination: subcutaneous injection into the lateral deltoid of the upper arm; Dosage of vaccination: 0.5 mL; Immunization procedure: saline will be administered at Day 0, and Ganwei® will be administered at Day 60；
Study: NCT06800937

Intervention type: OTHER
Intervention: Determination of sphingolipidomic profile
Description: The plasma/serum levels of the following sphingolipids will be measured: ceramides and dihydroceramides from C16 to C24, including 2 unsaturated ones (C18:1 and C24:1), sphingomyelins (those from C16 to C24 and the one C24:1), sphingosine, sphinganine, sphingosine-1-phosphate and sphinganine-1-phosphate.

Intervention type: OTHER
Intervention: Determination of sphingolipidomic profile
Description: The plasma/serum levels of the following sphingolipids will be measured: ceramides and dihydroceramides from C16 to C24, including 2 unsaturated ones (C18:1 and C24:1), sphingomyelins (those from C16 to C24 and the one C24:1), sphingosine, sphinganine, sphingosine-1-phosphate and sphinganine-1-phosphate.
Study: NCT06801171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive stimulation
Description: 12 sessions (one per week for 12 weeks) in group of cognitive stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mixed intervention
Description: 12 sessions (one per week for 12 weeks) in group of mixte stimulation (yoga, cognitive behavioral therapy, mindfullness meditation, positive psychology)
Study: NCT06801106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella
Description: is an airway clearance device that combines the resistive features of a positive expiratory pressure device with oscillations, which diminishes the mucus adhesiveness and decrease the collapsibility of airways

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung flute
Description: is a new oscillatory positive expiratory pressure (OPEP) device that produces a low frequency acoustic wave with vigorous exhalation that increases mucociliary clearance
Study: NCT06800807

Intervention type: OTHER
Intervention: Observation of several factors involved in eating and nutrition disorders
Description: Observation of symptomatology of eating and nutrition disorders, metacognitive beliefs, brooding and rumination.

Intervention type: OTHER
Intervention: Observation of several factors involved in eating and nutrition disorders
Description: Observation of symptomatology of eating and nutrition disorders, metacognitive beliefs, brooding and rumination.
Study: NCT06800378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Description: Zolpidem tartrate 10 mg tablet (taken before bedtime)

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Starch 10 mg tablet (taken before bedtime)
Study: NCT06801028

Intervention type: BIOLOGICAL
Intervention: injection Sekucinumab
Description: All patients with erythrodermic psoriasis (EP), who will receive subcutaneous injection of secukinumab at a dose of 300 mg once a week from week 0 to 4 followed by every 4 week. At weeks 0, 4, 8, 12, 16 and 20 the psoriasis area and severity index (PASI) will be recorded and adverse drug reactions, patient's satisfaction and recurrence will be observed.
Study: NCT06801561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: This group will be subjected to laser therapy. Er,Cr:YSGG will be used (Waterlase®, Biolase, USA) of a wavelength of 2780 nm at a power of 0.75 W using a frequency of 20 Hz and pulse duration of 140 µs. (33) Irradiation will be performed on the entire occlusal and at the hypomineralized areas. (34) The laser tip will pass in a uniform scanning motion steadily for 20 sec with relative isolation with 11% air and no water-cooling system. During the laser treatment, all safety measures will be followed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glass ionomer sealant
Description: This group will receive glass ionomer sealant. Conditioning of the surface will be done using polyacrylic acid (10%) conditioner for 20 seconds, then rinsed and dried. Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
Study: NCT06801093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital psychosocial tool
Description: Wysa is a digital psychosocial tool that provides AI conversational chatbot support. The conversational agent acts as a companion, and understands, empathizes, and guides users through exercises grounded in cognitive behavioral therapy (CBT), mindfulness, and motivational intervention. Participants can progressively work through learning different skills and practice them in their daily life. The app also provides a repository of tools to manage problems and SOS resources for high distress.
Study: NCT06800911

Intervention type: OTHER
Intervention: Questionnaires
Description: Metacognition Questionnaire Penn State Worry Questionnaire Ruminative Response Scale Anger Rumination scale Difficulties in Emotion Regulation Scale Emotional Eating subscale of the Dutch Eating Behavior Questionnaire
Study: NCT06699576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: HS-20093: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: HS-20093: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib: 12mg once daily (QD) orally
Study: NCT06279364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV Infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Tablet. Oral route of administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: IV infusion.
Study: NCT06699576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib: 12mg once daily (QD) orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin: administered as an IV infusion
Study: NCT06279364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion.
Study: NCT05326243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted chimeric antigen receptor T-cell
Description: Drug: Fludarabine~patients will receive a lymphodepletion chemotherapy with Fludarabine 25 mg/m2/day IV for 3 days on Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Drug: Cyclophosphamide~patients will receive a lymphodepletion chemotherapy with cyclophosphamide 300 mg/m2/day IV for 3 dys Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Biological: CD19 CAR-T~CD19 CAR-T cells will be administered using as a single dose at 0.1-9\*10\^6 cells/kg on Day 0 after completion of the lymphodepletion chemotherapy. The body weight calculated for PL001 dose is the actual body weight on the day of leukapheresis.
Study: NCT06331546

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-oxalate diet
Description: 4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-oxalate diet
Description: 4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-oxalate diet
Description: 4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium content (600-1000 mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-oxalate diet
Description: 4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium content (600-1000 mg/day)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: soluble oxalate gut absorption test
Description: Oral ingestion of 13C2-oxalate and sucralose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soluble oxalate gut absorption test
Description: Oral ingestion of 13C2-oxalate and sucralose.
Study: NCT05380804

Intervention type: DIAGNOSTIC_TEST
Intervention: cutaneous silent period (CSP) measurement
Description: CSP recordings are performed in the upper extremities using the same surface bar recording electrodes. Filters are set at 2 Hertz (Hz) to 10 kilo Hz, sensitivity is 200 microVolts (µV) and sweep speed is set at 200 milliseconds (ms). Stimulating electrode is placed on the index finger and recording bar electrode is placed on the abductor pollicis brevis (APB) muscle. During steady submaximal (50% of the maximal contraction) thumb abduction, 10 consecutive painful electrical stimuli of standard 80-milli Ampere (mA) intensity and 0.5-ms duration are applied to the index finger and responses are superimposed. CSP latency and duration are calculated and recorded. CSP latency is defined as the time between the stimulation and the onset of the silent period. CSP duration is calculated as the time interval between the beginning and end of the CSP.

Intervention type: DIAGNOSTIC_TEST
Intervention: cutaneous silent period (CSP) measurement
Description: CSP recordings are performed in the upper extremities using the same surface bar recording electrodes. Filters are set at 2 Hertz (Hz) to 10 kilo Hz, sensitivity is 200 microVolts (µV) and sweep speed is set at 200 milliseconds (ms). Stimulating electrode is placed on the index finger and recording bar electrode is placed on the abductor pollicis brevis (APB) muscle. During steady submaximal (50% of the maximal contraction) thumb abduction, 10 consecutive painful electrical stimuli of standard 80-milli Ampere (mA) intensity and 0.5-ms duration are applied to the index finger and responses are superimposed. CSP latency and duration are calculated and recorded. CSP latency is defined as the time between the stimulation and the onset of the silent period. CSP duration is calculated as the time interval between the beginning and end of the CSP.
Study: NCT04938232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous infusion
Study: NCT05823961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-linked hyaluronic acid eye drops
Description: Cross-linked hyaluronic acid (CLHA)-based eyedrops
Study: NCT06140927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will be administered ketamine at increasing doses followed by measurements of motor-evoked potentials.
Study: NCT05527587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature Connections Intervention
Description: 10 PLWD and their 10 caregivers will be examined for the effects of a park visit program on their behaviour and mood symptoms, cognition, and quality of life over the period of 8-weeks. If participants meet the study criteria, an initial education session on the health benefits of nature will be provided to the them. Participants will then be invited to participate in the park visit program which will have them visiting local parks or outdoors spaces with their caregivers. They will be encouraged to allocate approximately 120 minutes each week to outdoor park activities for 8 weeks. Participants will be provided with a visit passport to record a log of activities completed during the park visits. During the 8 weeks of intervention, participants will also participate in a weekly check-in meeting with other participants to discuss about their experiences with the park visits.
Study: NCT05605275

Intervention type: DIAGNOSTIC_TEST
Intervention: PCT levels
Description: All patients will have their serum PCT level recorded on the day of the positive blood culture and in the next three days.

Intervention type: DIAGNOSTIC_TEST
Intervention: PCT levels
Description: All patients will have their serum PCT level recorded on the day of the positive blood culture and in the next three days.

Intervention type: DIAGNOSTIC_TEST
Intervention: CRP levels
Description: All patients will have their serum CRP level recorded on the day of the positive blood culture and in the next three days.

Intervention type: DIAGNOSTIC_TEST
Intervention: CRP levels
Description: All patients will have their serum CRP level recorded on the day of the positive blood culture and in the next three days.

Intervention type: DIAGNOSTIC_TEST
Intervention: White blood cell count
Description: All patients will have their white blood cell (WBC) count recorded on the day of the positive blood culture and in the next three days.

Intervention type: DIAGNOSTIC_TEST
Intervention: White blood cell count
Description: All patients will have their white blood cell (WBC) count recorded on the day of the positive blood culture and in the next three days.

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count
Description: All patients will have their platelets count recorded on the day of the positive blood culture and in the next three days.

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count
Description: All patients will have their platelets count recorded on the day of the positive blood culture and in the next three days.
Study: NCT04876924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-711
Description: BBP-711, oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-711
Description: BBP-711, oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-711
Description: BBP-711, oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BBP-711

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BBP-711

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BBP-711
Study: NCT06311201

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal belt
Description: This was used for all women in both groups (A and B) for 8 weeks starting from the 7th days after delivery. The women was asked to wear the abdominal belt throughout the day except when bathing, eating and sleeping. The binder was worn over the skin directly or on a thin layer of clothing. The side of the abdominal binder without the straps was pulled over by the woman's stomach with one hand. The side of the binder with straps was stretched across the stomach and pulled to the center of the abdomen. The straps then was fitted into the buckles. Women were instructed not to wear the binder too tight or too loose as it might irritate the skin and produce difficulty in breathing creating discomfort. They were asked to inspect their skin regularly for any signs of sensitivity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal belt
Description: This was used for all women in both groups (A and B) for 8 weeks starting from the 7th days after delivery. The women was asked to wear the abdominal belt throughout the day except when bathing, eating and sleeping. The binder was worn over the skin directly or on a thin layer of clothing. The side of the abdominal binder without the straps was pulled over by the woman's stomach with one hand. The side of the binder with straps was stretched across the stomach and pulled to the center of the abdomen. The straps then was fitted into the buckles. Women were instructed not to wear the binder too tight or too loose as it might irritate the skin and produce difficulty in breathing creating discomfort. They were asked to inspect their skin regularly for any signs of sensitivity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: The Pilates exercise program for the study group (B) consisted of a 10-minute warm-up with low-intensity exercises, followed by a 40-minute central part with floor exercises like leg circles, kicks, and stretches. It included the classic hundred exercise, performed with proper form. Each exercise had two sets of 10 repetitions. The session ended with a 10-minute cool-down of stretching exercises, supervised by a physical therapist. The program was conducted three times per week, one hour per session, for eight weeks, starting from the 7th day after delivery.
Study: NCT06699576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab: administered as an IV infusion
Study: NCT06699420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishenyiqi dripping pills 1 bag, three times a day
Description: Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1 bag, three times a day
Description: Placebo, 1 bag once, three times a day, 12 months
Study: NCT06699706

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous theta-burst stimulation
Description: cTBS targets two regions: the dorsolateral prefrontal cortex (dlPFC) and the M1 area. Before the first treatment, each participant's resting motor threshold (RMT) will be determined using a five-step procedure for the primary motor cortex. RMT is defined as the minimum intensity required to elicit a motor response greater than 50 µV in at least 5 out of 10 consecutive trials in the right first dorsal interosseous muscle.~Participants will then undergo daily cTBS treatment three times a day for 7 consecutive days. Each stimulation session lasts 40 seconds, consisting of triplets of 50 Hz theta-burst stimulation repeated at 5 Hz, delivering a total of 600 pulses. Stimulation of the dlPFC target will be immediately followed by stimulation of the M1 target. To achieve cumulative aftereffects, the protocol will be repeated three times per day (a total of 3600 pulses/day) with two 15-minute breaks between sessions, timed with a stopwatch.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham continuous theta-burst stimulation
Description: The treatment pattern for the sham continuous theta-burst stimulation was similar to that for real stimulation. The sham coil is identical in appearance to the active coil, but it only produces sounds and sensations similar to those of the active coil on the scalp without generating a current, preventing participants from identifying their group assignment.
Study: NCT06053684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Non-Invasive Mechanical Servo Ventilation
Description: The active comparator arm will utilize a standard non-invasive mode to provide ventilation support

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation
Description: The experimental arm will utilize a NAVA mode to provide non-invasive ventilation support
Study: NCT04252547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Care
Description: The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother. A chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. The infant's heart rate and oxygen saturation will also continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weight is measured without a diaper change and his/her weight will be recorded. Then he/she will be taken back in the incubator to sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Care
Description: The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother. A chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. The infant's heart rate and oxygen saturation will also continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weight is measured without a diaper change and his/her weight will be recorded. Then he/she will be taken back in the incubator to sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before feeding when they are included in the study and then they will be breastfed by their mothers. The chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. Also, the infant's heart rate and oxygen saturation will continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weighed without a diaper change and his/her weight will be recorded. When the care process is over, it will be taken back in the incubator to sleep.
Study: NCT06801405

Intervention type: DRUG
Intervention: antibiotic prophylaxis
Description: Antibiotic prophylaxis before percutaneous nephrostomy